Apogee Therapeutics (NASDAQ:APGE) Announces Earnings Results, Misses Estimates By $0.25 EPS

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25), Zacks reports.

Apogee Therapeutics Price Performance

Shares of NASDAQ APGE traded up $4.01 during midday trading on Thursday, hitting $35.44. 1,063,354 shares of the company's stock were exchanged, compared to its average volume of 574,500. The firm's fifty day simple moving average is $39.35 and its 200-day simple moving average is $47.10. The company has a market cap of $1.60 billion, a PE ratio of -14.64 and a beta of 2.46. Apogee Therapeutics has a twelve month low of $29.10 and a twelve month high of $72.29.

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 4,540 shares of the company's stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the completion of the transaction, the insider now owns 258,073 shares in the company, valued at $12,583,639.48. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $40.58, for a total value of $608,700.00. Following the sale, the chief executive officer now owns 1,302,987 shares in the company, valued at $52,875,212.46. This trade represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,145 shares of company stock valued at $1,897,799 over the last three months. 36.10% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages recently weighed in on APGE. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a research note on Monday. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Finally, Canaccord Genuity Group initiated coverage on Apogee Therapeutics in a report on Monday, November 25th. They set a "buy" rating and a $89.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics has a consensus rating of "Buy" and a consensus price target of $88.83.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.